VAL ValiRx plc

0.1350GBp0.00%Mkt Cap: 1.94M $P/E: —

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperi…

Key Statistics

Company
Market Cap1.94M USD
Enterprise Value-352.67K USD
Revenue (TTM)35.51K USD
Gross Profit-6.79K USD
Net Income (TTM)-2.43M USD
Revenue/Share0.00 GBp
Last Price0.1350 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees11
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.22
EV/Revenue-9.93
P/S54.55
P/B0.34
EPS (TTM)0.00
EPS (Forward)-1.86
52W Range
0.12003% of range0.5690
52W High0.5690 GBp
52W Low0.1200 GBp
Profitability
Gross Margin-19.92%
Oper. Margin-63185.85%
EBITDA Margin0.00%
Profit Margin-7115.13%
ROE-78.18%
ROA-84.82%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.64M USD
CapEx (TTM)14.76K USD
FCF Margin-2592.20%
FCF Yield-47.52%
Net Debt-1.05M USD
Net Debt/EBITDA0.65
Balance Sheet
Debt/Equity0.00
Current Ratio10.98
Quick Ratio10.41
Book Value/Sh0.0040 GBp
Cash/Share0.0010 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBp
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateApr 6, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.32B
Float789.47M
Insiders8.77%
Institutions0.00%
Technical
SMA 500.1477 (-8.6%)
SMA 2000.2415 (-44.1%)
Beta-0.61
S&P 52W Chg14.58%
Avg Vol (30d)4.82M
Avg Vol (10d)4.47M
Technical Indicators
RSI (14)42.0
MACD-0.0044
MACD Signal-0.0055
MACD Hist.+0.0011
BB Upper0.1511 GBp
BB Middle0.1363 GBp
BB Lower0.1214 GBp
BB Width21.76%
ATR (14)0.0177 GBp
Vol Ratio (20d)0.01x